Valturna is licensed to treat high blood pressure in adults. A combination product, it contains two different medications that work together to lower blood pressure. This drug is often used for cases of high blood pressure that haven't responded well enough to just one medication. At this time, there are no approved "off-label" uses for Valturna.
In April 2012, it was decided that this medication should no longer be available, due to the risks it poses to people with diabetes or with moderate-to-severe kidney problems. Production will officially cease in July 2012.
Valturna can be useful for treating high blood pressure that has not responded adequately to other medications. It is also approved for use in people who will be unlikely to respond adequately to just one blood pressure medication, such as people with very high blood pressure, and for use in people already taking valsartan and aliskiren individually.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Valturna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;2011 April.
Food and Drug Administration, Center for Drug Evaluation and Research. FDA drug safety communication: new warning and contraindication for blood pressure medicines containing aliskiren (Tekturna) (4/20/2012). FDA Web site. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm300889.htm. Accessed April 25, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click